이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

aTyr Pharma 관리

관리 기준 확인 3/4

aTyr Pharma's CEO는 Sanjay Shukla, Nov2017 에 임명되었습니다 의 임기는 6.58 년입니다. 총 연간 보상은 $ 1.30M, 43.2% 로 구성됩니다. 43.2% 급여 및 56.8% 보너스(회사 주식 및 옵션 포함). 는 € 209.66K 가치에 해당하는 회사 주식의 0.2% 직접 소유합니다. 209.66K. 경영진과 이사회의 평균 재임 기간은 각각 5.7 년과 14.7 년입니다.

주요 정보

Sanjay Shukla

최고 경영자

US$1.3m

총 보상

CEO 급여 비율	43.2%
CEO 임기	6.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	15yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Sanjay Shukla 의 보수는 aTyr Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$1m	US$561k	-US$50m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$45m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$561k	-US$45m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$41m
Mar 31 2022	n/a	n/a	-US$39m
Dec 31 2021	US$2m	US$510k	-US$34m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$25m
Dec 31 2020	US$1m	US$470k	-US$16m
Sep 30 2020	n/a	n/a	-US$17m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$664k	US$450k	-US$24m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$30m
Dec 31 2018	US$1m	US$450k	-US$35m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$45m
Dec 31 2017	US$2m	US$403k	-US$48m

보상 대 시장: Sanjay 의 총 보상 ($USD 1.30M )은 German 시장( $USD 434.78K ).

보상과 수익: Sanjay 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sanjay Shukla (52 yo)

6.8yrs

테뉴어

US$1,300,525

보상

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sanjay Shukla	President	6.8yrs	US$1.30m	0.18% $ 216.5k
Jill Broadfoot	Chief Financial Officer	6.2yrs	US$677.84k	0.027% $ 33.0k
Nancy E. Krueger	General Counsel & Corporate Secretary	9.9yrs	US$651.28k	0.029% $ 35.3k
Xiang-Lei Yang	Founder	no data	데이터 없음	데이터 없음
Jayant Aphale	Vice President of Technical Operations	less than a year	데이터 없음	데이터 없음
Ashlee Dunston	Director of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Peter Villiger	Vice President of Corporate Development	4.7yrs	데이터 없음	데이터 없음
Danielle Campbell	VP of Human Resource	2.8yrs	데이터 없음	데이터 없음
Leslie Nangle	Vice President of Research	no data	데이터 없음	데이터 없음
Ying Buechler	Executive Director of Biologics Development & Manufacturing	no data	데이터 없음	데이터 없음
David King	Scientific Consultant	5.8yrs	US$717.31k	데이터 없음

5.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: 471A 의 관리팀은 노련하고 경험 (평균 재직 기간 5.7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sanjay Shukla	President	6.8yrs	US$1.30m	0.18% $ 216.5k
John Clarke	Independent Director	19yrs	US$120.84k	0.026% $ 31.4k
Paul Schimmel	Independent Director	19yrs	US$61.20k	1.45% $ 1.7m
Floyd Bloom	Member of Scientific Advisory Board	14.9yrs	데이터 없음	데이터 없음
Bruce Beutler	Member of Scientific Advisory Board	15.1yrs	데이터 없음	데이터 없음
Benjamin Cravatt	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Timothy Coughlin	Independent Chairman of the Board	7.4yrs	US$92.20k	0.074% $ 88.8k
Osamu Nureki	Member of Scientific Advisory Board	15yrs	데이터 없음	데이터 없음
Susan Ackerman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Wing Wong	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Nancy Ip	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jane Gross	Independent Director	5.2yrs	US$68.88k	0.0079% $ 9.5k

15.0yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: 471A 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 14.7 년).

aTyr Pharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director recently bought €170k worth of stock

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Independent Director recently bought €410k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

Independent Director recently bought €170k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

New major risk - Share price stability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Independent Director recently bought €410k worth of stock

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Independent Director recently bought €163k worth of stock

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

New 90-day high: €6.35

aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC

aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령